Bell John Irving 4

What Happened John Irving Bell, a director of Immunocore Holdings plc (IMCR), was granted an award of 27,492 derivative shares on 2026-05-27. The award is reported at $0.00 per share (total reported value $0) because it is a compensated equity grant subject to vesting rather than an open-market purchase.

Key Details

• Transaction date: 2026-05-27; filing date: 2026-05-28 (Form 4 accession 0001969932-26-000002). Filing appears timely.
• Transaction type: Grant / Award of derivative securities (code A); reported acquisition of 27,492 shares at $0.00.
• Shares owned after transaction: not specified in the provided filing summary.
• Vesting footnote: the shares vest at the earlier of (i) May 27, 2027 or (ii) the day before the issuer’s next annual general meeting, subject to continuous service (per footnote F1).
• No sale or exercise reported with this filing.

Context This was an equity award subject to future vesting, common as executive/director compensation. Such awards do not indicate an immediate cash purchase or sale and do not necessarily signal the insider’s market view. Retail investors should watch for future Form 4 entries when the award vests or if shares are sold, which would show actual changes in beneficial ownership or realized proceeds.